Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice. Longer summary

Scott Alexander discusses the 'compounding loophole' that allows compounding pharmacies to produce cheaper versions of GLP-1 agonist drugs like semaglutide (Ozempic). He explains how these pharmacies operate, the cost differences, safety concerns, and potential future implications. The post covers the legal basis for this practice during drug shortages, the impact on drug manufacturers like Novo Nordisk, and speculates on what might happen when the shortage ends. Scott also touches on the broader implications for drug pricing and availability. Shorter summary

Scott Alexander examines the complexities of abolishing the FDA and proposes more practical alternatives to increase medical innovation while maintaining safeguards. Longer summary

Scott Alexander discusses the challenges of abolishing the FDA, a popular libertarian idea. He explores various issues that would arise, such as the fate of prescription medications, drug contamination inspections, and the potential for exploitation by unethical companies. The post then proposes two more practical alternatives to complete FDA abolition: legalizing artificial supplements and creating an 'experimental drug' category. These suggestions aim to increase medical innovation and access while maintaining some safeguards. Shorter summary

Scott Alexander responds to comments on his post about new telemedicine regulations, addressing various concerns and criticisms raised by readers. Longer summary

Scott Alexander summarizes and responds to various comments on his original post about new telemedicine regulations. He addresses concerns about drug addiction, debates the effectiveness of telemedicine compared to in-person care, discusses the issue of 'pill mills', clarifies his analogy about blind people accessing Braille, responds to criticism of his characterization of Christian doctors, examines which part of the government is responsible for the regulations, and looks at how other countries handle telemedicine prescriptions. Shorter summary

Scott Alexander criticizes new DEA regulations that restrict telemedicine prescriptions for controlled substances, arguing they will harm patients and legitimate practices while failing to prevent abuse. Longer summary

Scott Alexander criticizes new DEA regulations that make it harder for telemedicine doctors to prescribe controlled substances. As a telepsychiatrist, he explains how these rules will negatively impact his practice and patients, especially those who rely on controlled substances for conditions like ADHD or anxiety. He argues that the new regulations, while intended to prevent overprescribing, will mainly create inconvenience for legitimate practitioners and patients while doing little to stop actual abusers. Scott outlines the loopholes in the law and how they highlight its absurdity, predicting that these rules will make telemedicine less accessible and effective in the long run. Shorter summary

Scott provides updates on efforts to get FDA approval for fluvoxamine as a COVID-19 treatment and reports on the early approval of Paxlovid. Longer summary

This post is an addendum to a previous article about Luvox and COVID-19 treatment. It updates readers on recent developments in the effort to get FDA approval for fluvoxamine (Luvox) as a COVID-19 treatment. Scott reports that Dr. Ed Mills and colleagues have found a way to submit an Emergency Use Authorization (EUA) application to the FDA for fluvoxamine, despite the initial hurdle of not having a sponsoring drug company. The post also mentions the FDA's approval of Paxlovid, another COVID-19 drug, which happened earlier than expected according to prediction markets. Shorter summary

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox. Longer summary

This post criticizes Vox's article on EpiPen price hikes, arguing that the problem isn't lack of regulation but over-regulation and cronyism. Scott Alexander contrasts the pharmaceutical industry with the unregulated chair industry, pointing out that chair prices don't suddenly spike 400%. He then details how FDA regulations and patent laws prevent competitors from entering the EpiPen market, despite the drug being off-patent and inexpensive to produce. The post highlights several failed attempts by companies to create generic versions of EpiPens, and how lobbying by the manufacturer Mylan has helped maintain their monopoly. Scott uses an extended analogy comparing the situation to a hypothetical government-controlled chair market to illustrate the absurdity of the current system. Shorter summary

Scott Alexander presents a satirical list of fictional drugs banned by the FDA, each with an absurd reason for its prohibition. Longer summary

This post is a humorous fictional list of drugs banned by the FDA. Each drug is presented with a profile describing its intended use, followed by an absurd or ironic reason for its ban. The drugs cover a range of conditions from weight loss to erectile dysfunction, with each ban highlighting unexpected consequences or bizarre side effects. The post uses scientific terminology and real medical concepts to create a sense of plausibility, before subverting expectations with the ridiculous reasons for the bans. Shorter summary